312 results
Page 9 of 16
8-K
EX-99.1
7wv5p5npr61l226hj
24 Oct 12
Regeneron Reports Third Quarter 2012 Financial and Operating Results
12:00am
8-K
EX-99.1
lez4isqo9i9h4
25 Jul 12
Regeneron Reports Second Quarter 2012 Financial and Operating Results
12:00am
8-K
EX-99.1
brhuzid8ipcbgpy
8 May 12
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
12:00am
8-K
EX-99.1
7vk 7f5mmk
26 Apr 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
xq6ugwbh13r1ppc
13 Feb 12
Regeneron Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
12:00am
8-K
EX-99.1
m779pxj uxub
3 Jan 12
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
12:00am
8-K
w2fyf
3 Jan 12
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
12:00am
8-K
EX-99.1
eohdoicnd27ii9c6me
5 Dec 11
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
12:00am
8-K/A
EX-99.1
9aawrj fxx
22 Nov 11
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
12:00am
8-K
EX-99.1
szeet6 oques9
27 Oct 11
Regeneron Reports Third Quarter 2011 Financial and Operating Results
12:00am
8-K
EX-1.1
e1nez0xo
24 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
nr1 ghy4u
19 Oct 11
Other Events
12:00am
8-K
EX-99.1
2t738b631c1 qd11br6s
17 Aug 11
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
12:00am